Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 13, 2018. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
This filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on specific share acquisition transactions.
| Transaction Date | Instrument | Price per Share | Total Volume | Exchange |
|---|---|---|---|---|
| April 12, 2018 | Ordinary Shares (25p each) | £14.4089 | 340 shares | London Stock Exchange (XLON) |
Material Changes
The filing reports no material changes to the company's financial position or operations. It details routine acquisitions of ordinary shares by nine executives following the re-investment of dividends paid on April 12, 2018, under the Company's Share Reward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transactions were executed automatically via dividend re-investment plans.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ordinary shares via dividend re-investment, not open market purchases or sales.
- Participants: Nine PDMRs participated, including the CEO (Ms E Walmsley), CFO (Mr S Dingemans), and Company Secretary (Mrs V A Whyte).
- Share Price: The execution price for all transactions was £14.4089 per share.
- Volume: The total number of shares acquired across all executives was 340.
- Financial Data: This document does not provide quarterly or annual financial performance data; investors should refer to Form 20-F for those metrics.